Contact us for free information or to start a free case review.
Baxter International Inc. announced yesterday it has halted shipments of a popular infusion pump because of dangerous design problems. The company said about 250,000 of its Colleague brand pump used to administer intravenous medicines to patients might have a product flaw responsible for three deaths and six serious injuries.
Baxter said it plans on fixing the medical products, but the infusion pump recall forced the company to take a $65 million charge for the second quarter. A design flaw was first reported to customers in March that could disrupt infusions of intravenous therapies to patients. The decision to withhold further shipments was made after Baxter said it discovered a separate problem with certain models of the pump.
The FDA classified the Baxter Colleague recall as a “Class I,” or the most serious type of recall issued. Baxter must fix the estimated 250,000 devices already in use, but the company said only a small number of the devices have been affected by the safety flaws.
Copyright © 2001 - 2012 Online Lawyer Source
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.